Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | SPR | P35270 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667129 | 0.82 | KDM4E (0.75) | KDM4ELMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL5135088 | 0.82 | KDM4E (0.60) | KDM4ELMNASMN1; SMN2POLBTSHR | |
| SCHEMBL2762847 | 0.80 | SMN1; SMN2 (0.62) | KDM4ELMNASMN1; SMN2POLBTSHR | |
| SCHEMBL28801726 | 0.79 | KDM4E (0.49) | KDM4ELMNASMN1; SMN2POLBTSHR | |
| SCHEMBL8068292 | 0.78 | KDM4E (0.68) | KDM4ELMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL23308872 | 0.78 | TSHR (0.59) | KDM4ELMNASMN1; SMN2POLBTSHR | |
| SCHEMBL5632154 | 0.78 | TSHR (0.59) | KDM4ELMNASMN1; SMN2POLBTSHR | |
| SCHEMBL2104486 | 0.78 | TSHR (0.59) | KDM4ELMNASMN1; SMN2POLBTSHR | |
| SCHEMBL6431253 | 0.78 | KEAP1 (0.57) | KDM4EPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL1631053 | 0.78 | TSHR (0.65) | KDM4ELMNASMN1; SMN2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160358-A1 | Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure | SPEEDEL PHARMA AG (CH) | 2010-06-24 | — | — | US | disclosed |
| CN-101257947-A | Pyridylsulfonamidyl-pyrimidines for the prevention of blood vessel graft failure | SPEEDEL PHARMA AG (CH) | 2008-09-03 | — | — | CN | disclosed |
| EP-1924325-A2 | PYRIDYLSULFONAMIDYL-PYRIMIDINES FOR THE PREVENTION OF BLOOD VESSEL GRAFT FAILURE | Speedel Pharma AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007031501-A2 | PYRIDYLSULFONAMIDYL-PYRIMIDINES FOR THE PREVENTION OF BLOOD VESSEL GRAFT FAILURE | SPEEDEL PHARMA AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| EP-1454625-A1 | Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies | Speedel Development AG (CH) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160358-A1 | Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure | PDXK, CBS, C1S | KDM4E 3258/4885LMNA 3499/4885SMN1; SMN2 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.